What exactly did Morgan Stanley do on March 13, 2026 for SANA?

On March 13, 2026 at 01:05 PM Morgan Stanley reiterated an **Overweight** rating on Sana Biotechnology, Inc. The firm cited a “meaningful platform level de-risking event” and did not publish a new price target.

How should I interpret the SANA analyst rating for my portfolio?

A maintained Overweight suggests the analyst expects SANA to outperform peers. Use the SANA analyst rating with your risk profile and pipeline milestones before changing positions.

Did the Morgan Stanley note include a new SANA price target?

No. The StreetInsider summary of Morgan Stanley’s note did not include a new SANA price target. Investors should await a full report for any target updates.

What is Meyka AI’s view and grade on SANA?

Meyka AI rates SANA with a grade of **B**. The grade reflects S&P 500 comparison, sector performance, financial growth, key metrics, and analyst consensus. Grades are not guarantees or investment advice.

Analyst Ratings

Morgan Stanley Maintains Overweight on Sana Biotechnology, Inc. (SANA) March 2026

ByHuzaifa Zahoor March 14, 2026

Morgan Stanley maintained an Overweight rating on Sana Biotechnology, Inc. (SANA) on March 13, 2026. The firm called a recent company update a “meaningful platform level de-risking event.” This SANA analyst rating action was logged at 01:05 PM and coincided with a 1.82% ($0.06) intraday move. Investors should note the rating was reiterated, not upgraded or downgraded, and no new price target was published in the note.